View ValuationGRAIL 将来の成長Future 基準チェック /26GRAILの収益は年間5.8%で減少すると予測されていますが、年間収益は年間23.1%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-25.3% 1%なると予測されています。主要情報-5.8%収益成長率1.04%EPS成長率Biotechs 収益成長25.6%収益成長率23.1%将来の株主資本利益率-25.26%アナリストカバレッジGood最終更新日06 May 2026今後の成長に関する最新情報分析記事 • May 08Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter ResultsA week ago, GRAIL, Inc. ( NASDAQ:GRAL ) came out with a strong set of first-quarter numbers that could potentially lead...Price Target Changed • Mar 29Price target decreased by 18% to US$72.40Down from US$88.00, the current price target is an average from 5 analysts. New target price is 49% above last closing price of US$48.49. Stock is up 80% over the past year. The company is forecast to post a net loss per share of US$11.02 next year compared to a net loss per share of US$11.11 last year.Price Target Changed • Feb 22Price target decreased by 13% to US$101Down from US$115, the current price target is an average from 4 analysts. New target price is 100% above last closing price of US$50.21. Stock is up 23% over the past year. The company is forecast to post a net loss per share of US$10.95 next year compared to a net loss per share of US$11.11 last year.お知らせ • Jan 15GRAIL, Inc. Provides Earnings Guidance for the Full Year 2025GRAIL, Inc. provided earnings guidance for the full year 2025. Revenue is expected to be between $147 million and $148 million, approximately 17% to 18% growth over 2024.すべての更新を表示Recent updates分析記事 • May 08Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter ResultsA week ago, GRAIL, Inc. ( NASDAQ:GRAL ) came out with a strong set of first-quarter numbers that could potentially lead...ライブニュース • May 07GRAIL Delivers 28% Revenue Growth as Galleri Test Gains Momentum and FDA Advances ReviewQ1 2026 revenue rose 28% year over year, driven by a 37% increase in Galleri test sales to more than 56,000 tests. The company reported an operating loss of $135.8 million and a net loss attributable to common shareholders of $93.2 million in the quarter. The FDA accepted the PMA submission for Galleri, while GRAIL moved to integrate the test into Epic’s electronic health record platform and insiders, including Illumina and key executives, sold shares. For you as an investor, the story here is about commercial traction versus cash burn. Higher Galleri volumes and the 28% revenue growth signal that more physicians and health systems are using the test, which ties directly to management’s focus on broader adoption. At the same time, the operating and net losses underline that GRAIL is still in a capital-intensive phase where scale and regulatory progress are critical. The FDA’s acceptance of the PMA submission for Galleri, based on PATHFINDER 2 and NHS-Galleri trial data, takes the company further along the regulatory path, which can be important for payer discussions and health system uptake. Planned integration into Epic by the end of 2026 could make ordering and tracking Galleri tests easier for clinicians across the US, potentially affecting test volumes over time. Investors may also pay attention to the pattern of insider selling, including by Illumina, as one data point when assessing sentiment around the company’s current trajectory.ナラティブ更新 • May 07GRAL: Future Returns Will Reflect Trial Outcomes And Reimbursement ProgressNarrative Update on GRAIL Analysts have trimmed their average price target for GRAIL by incorporating lower profit margin assumptions and a slightly higher future P/E of about 101x, following mixed reactions to recent study readouts and reimbursement uncertainty. Analyst Commentary Recent research updates on GRAIL reflect a split tape, with some firms trimming price targets after the NHS Galleri readout and reimbursement uncertainty, while others still see room for upside based on the company’s test portfolio and addressable market.Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$2.29 loss per share (improved from US$3.10 loss in 1Q 2025). Revenue: US$40.8m (up 28% from 1Q 2025). Net loss: US$93.2m (loss narrowed 12% from 1Q 2025). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.お知らせ • Apr 30GRAIL, Inc., Annual General Meeting, Jun 18, 2026GRAIL, Inc., Annual General Meeting, Jun 18, 2026.Board Change • Apr 29High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Bill Chase is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 23GRAIL, Inc. to Report Q1, 2026 Results on May 05, 2026GRAIL, Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026ナラティブ更新 • Apr 19GRAL: Future Returns Will Depend On Upcoming FDA Approval DecisionAnalysts have trimmed GRAIL's average price target to about $67.71 from $72.40. They cited updated models that factor in recent price target cuts following the NHS-Galleri topline readout and lingering uncertainty around broad reimbursement, even as revenue growth and margin assumptions are slightly adjusted.Recent Insider Transactions • Apr 17CEO & Director recently sold US$6.2m worth of stockOn the 8th of April, Robert Ragusa sold around 124k shares on-market at roughly US$49.92 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$15m.Recent Insider Transactions Derivative • Apr 08CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 133k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of April. If the sale is conducted around the recent share price of US$51.74, it would amount to US$6.9m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Robert's direct individual holding has increased from 205.85k shares to 218.25k. Company insiders have collectively sold US$23m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Apr 08GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A StrikeoutSummary GRAIL, Inc. (formerly an Illumina subsidiary) remains a buy despite missing the NHS-Galleri trial’s primary endpoint. Galleri’s commercial viability is underscored by 31% YoY U.S. revenue growth and expanding partnerships, including Samsung. A strong cash position ($904.4M) supports operations through 2030, offsetting trial extension and sales force expansion costs. Revised TAM-based valuation implies $78/share (~43% upside), reflecting immense long-term potential for liquid biopsy adoption. Read the full article on Seeking Alphaお知らせ • Apr 08GRAIL, Inc. Announces Integration of Galleri Test into Epic Electronic Health Record PlatformGRAIL, Inc. announced a collaboration with Epic to bring the Galleri multi-cancer early detection test into one of the nation's most widely used electronic health record platforms, supporting broader adoption across health systems in the United States. Epic is a leading EHR platform used by many of the largest and most advanced health systems. Integration through Epic Aura will allow interested health systems and their healthcare providers to order the Galleri test directly at the point of care, receive results, and manage patient follow-up seamlessly within their existing native EHR and within their existing clinical workflows. Through this integration, clinicians using Epic can access the Galleri test within their native EHR environment, helping to eliminate administrative burden, reduce manual processes, and improve the overall provider and patient experience. Implementation planning began in the first quarter of 2026, including initial integrations and early adopter programs. GRAIL will work closely with Epic and AWS, the preferred cloud provider for GRAIL, along with any interested health systems, community healthcare providers, and retail health clinics to support workflow alignment, training and deployment success. Broad availability is expected by the end of 2026. The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear — when they can be easier to treat and are potentially curable. Galleri is the only available MCED test with demonstrated performance in patients screened for cancer. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market. The Galleri test doubles the number of cancers detected when added to standard of care cancer screening, and has the lowest false positive rate of any MCED test. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.ナラティブ更新 • Apr 05GRAL: Future Returns Will Hinge On Upcoming Regulatory And Coverage MilestonesNarrative Update on GRAIL The analyst price target for GRAIL has been reduced by $11.00. This change reflects recent cuts across firms citing the NHS Galleri study missing its primary endpoint and greater uncertainty around broad reimbursement, even as analysts still reference GRAIL's position in multi cancer early detection and upcoming regulatory and coverage milestones.Price Target Changed • Mar 29Price target decreased by 18% to US$72.40Down from US$88.00, the current price target is an average from 5 analysts. New target price is 49% above last closing price of US$48.49. Stock is up 80% over the past year. The company is forecast to post a net loss per share of US$11.02 next year compared to a net loss per share of US$11.11 last year.ナラティブ更新 • Mar 21GRAL: Future Returns Will Depend On NHS Study OutcomeNarrative Update: GRAIL Analyst Price Target Shift The updated analyst fair value estimate for GRAIL has moved from $88.00 to $83.40 as analysts factor in lower published price targets following the NHS Galleri study missing its primary endpoint and increased uncertainty around broad reimbursement, while still modeling higher revenue, stronger profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research shows a mix of optimism and caution around GRAIL, with several firms revising price targets after the NHS Galleri study update and recent quarterly results.お知らせ • Mar 13+ 1 more updateGRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026GRAIL, Inc. announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. Ragusa will remain on GRAIL's Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. Ofman joined GRAIL in 2019 and brings extensive experience in clinical medicine, biopharmaceutical leadership, health policy and precision medicine. He has served on numerous industry Boards, including BIO and the Precision Medicine Coalition. Before joining GRAIL, Ofman spent more than 15 years at Amgen, most recently as Senior Vice President, Global Value, Access and Policy. Earlier in his career, he was a faculty member in the Department of Medicine and Health Services Research at the UCLA School of Medicine and the Division of Digestive Diseases at Cedars-Sinai Medical Center, and served as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp.Recent Insider Transactions • Mar 11CEO & Director recently sold US$409k worth of stockOn the 9th of March, Robert Ragusa sold around 8k shares on-market at roughly US$48.48 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$7.4m.新しいナラティブ • Mar 08Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection PotentialCatalysts About GRAIL GRAIL focuses on multi cancer early detection through its Galleri screening test and related clinical programs. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 06GRAL: Future Returns Will Hinge On NHS Study And FDA DecisionThe analyst fair value estimate for Grail has been trimmed from $114.50 to $88.00 as analysts factor in lower revenue growth and profit margin assumptions following the NHS Galleri readout and increased uncertainty around broad reimbursement. Analyst Commentary Street research on Grail has shifted meaningfully following the NHS Galleri top line readout, with several firms reducing price targets and reassessing the risk and reward profile around Galleri adoption and reimbursement.Recent Insider Transactions Derivative • Mar 03CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 41k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$53.23, it would amount to US$2.2m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Robert's direct individual holding has increased from 127.65k shares to 173.43k. Company insiders have collectively sold US$20m more than they bought, via options and on-market transactions in the last 12 months.新しいナラティブ • Feb 22NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening AdoptionCatalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?Price Target Changed • Feb 22Price target decreased by 13% to US$101Down from US$115, the current price target is an average from 4 analysts. New target price is 100% above last closing price of US$50.21. Stock is up 23% over the past year. The company is forecast to post a net loss per share of US$10.95 next year compared to a net loss per share of US$11.11 last year.New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 3.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$539m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Significant insider selling over the past 3 months (US$7.6m sold).Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$11.11 loss per share (improved from US$63.54 loss in FY 2024). Revenue: US$147.2m (up 17% from FY 2024). Net loss: US$408.4m (loss narrowed 80% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.ナラティブ更新 • Feb 20GRAL: Future Returns Will Hinge On Upcoming NHS Trial ReadoutThe average analyst price target for Grail has edged down by $0.50 to about $114.50, as analysts balance optimism around upcoming trial readouts and potential regulatory milestones with a more cautious stance after the stock's very large move earlier in 2025 and ongoing execution risks. Analyst Commentary Recent research on Grail reflects a mix of enthusiasm for its position in multi cancer early detection and caution around valuation and execution timelines.お知らせ • Feb 20GRAIL, Inc. Announces NHS Galleri Trial Demonstrates A Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection RateGRAIL, Inc. announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years in 142,000 demographically representative participants aged 50 to 77. The clinical performance of Galleri has been rigorously established in several studies, and the NHS-Galleri trial was designed to demonstrate population-level impact through the reduction of late stage cancer diagnoses and increased cancer detection rate within the NHS to inform a decision about a national screening program in England. For the US market, the Galleri premarket approval application pending review by the FDA also includes metrics from the NHS-Galleri trial that are focused on test performance, clinical validation, and the clinical benefit of detection at Stages I through III, including reduction in Stage IV cancer diagnoses. Key trial results include: The primary endpoint of statistically significant Stage III-IV reduction was not observed. However, there was a favorable trend toward fewer Stage III-IV cancers in a pre-specified group of 12 deadly cancers in the intervention arm after the prevalent screening round. Adding Galleri to standard of care screening resulted in a substantial and clinically meaningful reduction in Stage IV diagnoses compared with standard of care alone across the pre-specified group of 12 deadly cancers. Stage IV diagnoses in these cancers decreased with each year of sequential screening, with a greater than 20% reduction in the second and third rounds. Similar reductions were observed across all cancers. Annual screening with the Galleri test plus standard of care screening resulted in a four-fold improvement in the overall cancer detection rate compared to standard of care screening alone in England for breast, colorectal, cervical and high risk lung cancer. Substantial increase in the absolute number of Stage I-II cancers in the 12 pre-specified deadly cancer types that are typically found in late stages were observed in the intervention arm. Screening with the Galleri test resulted in a substantial reduction in the number of cancers detected clinically through emergency presentation, which are associated with significantly higher mortality and healthcare costs. The Galleri test's performance – positive predictive value (PPV), specificity and Cancer Signal of Origin (CSO) accuracy – was consistent with the range previously reported from GRAIL's North American studies. Importantly, no serious safety concerns were reported in participants who received the Galleri test in the NHS-Galleri trial. Additional analyses are underway to better understand these rich data, and detailed results will be submitted for presentation at the ASCO 2026 Annual Meeting. Of note, there was a higher than anticipated incidence of Stage III cancers in the NHS-Galleri trial. In both the US and the NHS data, the time to diagnostic resolution appears to improve over time as physicians gain experience with the Galleri test and diagnostic workup. The number and distribution of cancer stages across screening rounds suggests the potential for a stronger effect with longer follow up as data matures, and GRAIL plans to extend the trial's follow up period by 6-12 months.お知らせ • Feb 16GRAIL, Inc. to Report Q4, 2025 Results on Feb 19, 2026GRAIL, Inc. announced that they will report Q4, 2025 results After-Market on Feb 19, 2026ナラティブ更新 • Feb 04GRAL: Future Returns Will Depend On NHS Readout And Execution ConsistencyNarrative Update Analysts have lifted their price target on GRAIL from $105 to $115, citing refreshed models that reflect updated assumptions for growth, margins and future P/E. Recent research highlights steady execution, the long term Galleri opportunity, and the absence of thesis changing developments in recent results.お知らせ • Jan 30GRAIL, Inc. Submits FDA Premarket Approval Application for the Galleri®? Multi-Cancer Early Detection TestGRAIL, Inc. announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri®? multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018. The PMA submission is focused on the test performance and safety results from 25,490 consented participants in the US-based PATHFINDER 2 study with one year of follow up and from the prevalent screening round (first year) of the NHS-Galleri trial, the largest, and only, randomized, controlled trial of any MCED test in an intended use population. The submission is also supported by a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated PMA version that has been submitted to the FDA for premarket approval. About the NHS-Galleri trial (NCT05611632) The NHS-Galleri trial is the first and only prospective, randomized, controlled trial to assess the clinical utility and performance of a multi-cancer early detection test for population screening when added to standard care. PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of the Galleri in approximately 35,000 individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. The primary objectives of the study are 1) to evaluate the safety and performance of theGalleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the Galleri MCED test across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted CSO to determine if a cancer is present.ナラティブ更新 • Jan 20GRAL: Future Returns Will Hinge On NHS Trial And Execution RisksAnalysts have nudged their price target on GRAIL up to $110 from $85, citing steady execution, a modest Q4 revenue beat, and the longer term opportunity for the Galleri test, despite the inherent risks that come with new technologies. Analyst Commentary Analysts see GRAIL's recent results as an incremental step rather than a major reset, with views split between confidence in execution and caution around key milestones like the NHS Galleri trial readout.お知らせ • Jan 15GRAIL, Inc. Provides Earnings Guidance for the Full Year 2025GRAIL, Inc. provided earnings guidance for the full year 2025. Revenue is expected to be between $147 million and $148 million, approximately 17% to 18% growth over 2024.ナラティブ更新 • Jan 06GRAL: Long Term MCED Opportunity And Execution Risks Will Shape Future ReturnsAnalysts have raised their price target range for GRAIL to about $85 from around $38, citing updated post-Q3 estimates and what they view as a significant long-term commercial opportunity for the Galleri multi-cancer early detection test, while also highlighting the risks associated with this type of novel technology. Analyst Commentary Bullish Takeaways Bullish analysts see the increase in the price target range to about $85 as a reflection of what they view as a sizeable commercial runway for the Galleri multi cancer early detection test over the long term.ナラティブ更新 • Dec 16GRAL: Future MCED Policy Shifts Will Drive Upside Despite Execution RisksAnalysts have raised their price target on GRAIL to $105 from $96.67, citing updated post earnings estimates and growing confidence in the long term commercial potential of the Galleri multi cancer early detection platform, despite ongoing technology and regulatory risks. Analyst Commentary Recent Street research reflects a meaningful reset in expectations for GRAIL, with multiple price target increases grounded in updated post earnings models and a clearer view of Galleri's commercial runway.Recent Insider Transactions • Dec 07CEO & Director recently sold US$3.8m worth of stockOn the 3rd of December, Robert Ragusa sold around 40k shares on-market at roughly US$95.24 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$5.1m. Robert has been a net seller over the last 12 months, reducing personal holdings by US$7.8m.Recent Insider Transactions Derivative • Dec 04Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of December. If the sale is conducted around the recent share price of US$99.15, it would amount to US$2.5m. Since March 2025, Aaron's direct individual holding has increased from 45.05k shares to 78.95k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.ナラティブ更新 • Dec 01GRAL: Risks From Clinical Data and Execution Will Remain a Key ConcernAnalysts have raised their price target for GRAIL from approximately $90 to $97 per share, citing strengthened confidence in the company’s long-term growth prospects. This outlook is driven by recent developments and opportunities in multi-cancer early detection.ナラティブ更新 • Nov 17GRAL: Confidence Will Increase With Upcoming Clinical Data and Legislative ProgressAnalysts have raised their price target for GRAIL from $61.50 to $90.00. This change reflects increased confidence in the company’s long-term prospects and growth potential, following recent updates and a positive outlook on its multi-cancer early detection technology.New Risk • Nov 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$538m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Significant insider selling over the past 3 months (US$5.7m sold).お知らせ • Nov 14GRAIL, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.GRAIL, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$2.46 loss per share (improved from US$3.94 loss in 3Q 2024). Revenue: US$36.2m (up 26% from 3Q 2024). Net loss: US$89.0m (loss narrowed 29% from 3Q 2024). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.お知らせ • Nov 08GRAIL, Inc. announced that it has received $324.999987 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd., Samsung C&T CorporationOn November 7, 2025, GRAIL, Inc closed the transaction. The transaction included participation from 17 investors.ナラティブ更新 • Nov 01GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory ShiftsAnalysts have raised GRAIL's fair value estimate from $56.50 to $61.50 per share, citing greater confidence in the company's platforms, ongoing clinical milestones, and evolving market opportunities as key drivers for the upward revision. Analyst Commentary Bullish Takeaways Bullish analysts highlight growing confidence in GRAIL's platforms.お知らせ • Oct 30GRAIL, Inc. to Report Q3, 2025 Results on Nov 12, 2025GRAIL, Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025お知らせ • Oct 21Grail, Inc. and University of Oxford to Present Long-Term Data from the Symplify Study Evaluating the Galleri®? Multi-Cancer Early Detection Test in Symptomatic Individuals At the Early Detection of Cancer ConferenceGRAIL, Inc. and the University of Oxford announced that positive long-term results from an extended registry follow-up of the SYMPLIFY study will be presented on Oct. 21 at the Early Detection of Cancer Conference (EDCC) in Portland, Oregon. SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primary care and were referred for diagnostic follow-up for suspicion of cancer. In SYMPLIFY, the Galleri®? test was used to assess blood samples from more than 6,000 participants with symptoms of cancer who followed standard diagnostic pathways. However, as a non-interventional study, the results of the tests were unknown to physicians and did not inform the approach to diagnosis. No MCED results were returned to participants or their clinicians during the study. Previous SYMPLIFY results showed potential of MCED testing in people with symptoms suggestive of cancer Most people diagnosed with cancer visit primary care with symptoms before diagnosis1. The fact that, in all but one of the additional patients diagnosed with cancer, a Galleri CSO prediction correctly identified the cancer type, including in many cases where the symptoms were non-specific, further reinforces the value of the Galleri test's CSO capability.ナラティブ更新 • Oct 18FDA Approval And NHS Studies Will Transform Cancer DetectionAnalysts have raised their price target on GRAIL significantly, from $43 to $75. They cite growing confidence in the company's platforms, anticipated improvements in test performance, and the potential impact of future legislative changes as reasons for this adjustment.Recent Insider Transactions • Oct 18CEO & Director recently sold US$499k worth of stockOn the 15th of October, Robert Ragusa sold around 7k shares on-market at roughly US$68.88 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$5.1m. Robert has been a net seller over the last 12 months, reducing personal holdings by US$4.0m.お知らせ • Oct 18GRAIL, Inc. Announces Positive Performance and Safety Results from its Registrational Pathfind 2 StudyGRAIL, Inc. announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. The largest interventional study of an MCED test in the United States to date, the prospective PATHFINDER 2 study includes 35,878 enrolled participants across the United States and Canada in a broad, intended-use population of adults aged 50 and older with no clinical pinpoint of cancer. Results were presented from a pre-specified analysis of the first 25,578 participants with at least 12 months of follow-up as of Dec. 31, 2024. The likelihood of receiving a cancer diagnosis following a positive test result (positive predictive value) was 61.6%, substantially higher than in the previous PATHFINDER study of Galleri. Since PATHFINDER 2 is a prospective clinical trial where the cancer status of participants is unknown at the outset, episode sensitivity - the ability to detect cancer that could be confirmed within 12 months after the blood draw - is a performance measure of the study. Data from this study will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premium approval (PMA) application, along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated version that GRAIL plans to submit to the FDA for premarket approval. The primary objectives of the study are 1) to evaluate the safety and performance of the Galleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the GalleriMCED test across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal detected does not rule out cancer. A test result of Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirmatory diagnostic evaluation by medically establish procedures (e.g., Imaging) to confirm cancer. The Galleri test was developed -- and its performance characteristics were determined -- by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about GRAIL, Inc. (the "Company"), include the benefits and use of the Galleri test, the potential of the Galleri MCED tests, expectations regarding the final results of the PATHFINDER 2 Study, upcoming events and presentations, the timeline and results of a bridging analysis to the FDA, the applicability of the Galleri test, and the applicability of the Galler test, and the timeline for completion of the PMO and the timeline for completion of The PMO and the first phase of the study.お知らせ • Oct 17GRAIL, Inc. announced that it expects to receive $110.000075 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd and Samsung C&T CorporationGRAIL, Inc. entered into a stock purchase agreement for issuance of 1,570,308 common shares at a price of $70.05 per share for gross proceeds of $110,000,075.4 on October 16, 2025. The transaction included participation from new investors Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd. and Samsung C&T Corporation. The Private Placement is exempt from the registration requirements of the Securities Act, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) and/or Rule 506 of Regulation D under the Securities Act and in reliance on similar exemptions under applicable state laws. The transaction closing is subject to regulatory approvals.Recent Insider Transactions Derivative • Oct 16President notifies of intention to sell stockJoshua Ofman intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of October. If the sale is conducted around the recent share price of US$69.29, it would amount to US$1.0m. Since March 2025, Joshua's direct individual holding has increased from 76.44k shares to 166.72k. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Oct 10President recently sold US$5.1m worth of stockOn the 6th of October, Joshua Ofman sold around 81k shares on-market at roughly US$62.50 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Joshua has been a net seller over the last 12 months, reducing personal holdings by US$6.9m.ナラティブ更新 • Oct 04FDA Approval And NHS Studies Will Transform Cancer DetectionAnalysts have raised their price target for GRAIL from $40.50 to $56.50. They cite strengthened confidence in the company's platforms, positive expectations for future study results, and anticipation of supportive legislative developments.Recent Insider Transactions Derivative • Oct 03President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of October. If the sale is conducted around the recent share price of US$62.06, it would amount to US$601k. Since December 2024, Joshua's direct individual holding has increased from 72.25k shares to 104.99k. Company insiders have collectively sold US$9.0m more than they bought, via options and on-market transactions in the last 12 months.New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$501m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).Reported Earnings • Aug 13Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: US$3.19 loss per share (improved from US$51.06 loss in 2Q 2024). Revenue: US$35.5m (up 11% from 2Q 2024). Net loss: US$114.0m (loss narrowed 93% from 2Q 2024). Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.お知らせ • Aug 13GRAIL, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2025GRAIL, Inc. reported impairment charges for the second quarter ended June 30, 2025. For the quarter, the company reported goodwill and intangible impairment of $28,000,000 against $1,420,936,000 a year ago.お知らせ • Jul 30GRAIL, Inc. to Report Q2, 2025 Results on Aug 12, 2025GRAIL, Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025Recent Insider Transactions Derivative • Jul 16Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of July. If the sale is conducted around the recent share price of US$40.18, it would amount to US$321k. Since September 2024, Aaron's direct individual holding has increased from 15.01k shares to 83.87k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jul 01President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of June. If the sale is conducted around the recent share price of US$48.39, it would amount to US$469k. Since September 2024, Joshua's direct individual holding has increased from 72.25k shares to 110.81k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Jun 30+ 4 more updatesGRAIL, Inc.(NasdaqGS:GRAL) dropped from Russell Midcap Value IndexGRAIL, Inc.(NasdaqGS:GRAL) dropped from Russell Midcap Value Indexお知らせ • Jun 18GRAIL, Inc. Announces Positive Top-Line Results from The Galleri PATHFINDER 2 Registrational StudyGRAIL, Inc. announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study. PATHFINDER 2 was initiated in 2021 to evaluate the safety and performance of the Galleri®? multi-cancer early detection (MCED) test when added to standard of care single cancer screening in 35,878 adults over 50 years of age with no clinical suspicion of cancer. PATHFINDER 2 study results will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premarket approval application (PMA), along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA bridging analyses to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated version that GRAIL plans to submit to the FDA for premarket approval. The PMA for Galleri is currently in process with a modular submission under a Breakthrough Device Designation from the FDA. GRAIL expects to complete the PMA modular submission in the first half of 2026. Detailed results from the PATHFINDER 2 Study (NCT05155605). PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of Galleri in approximately 35,000 individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. The primary objectives of the study are 1) to evaluate the safety and effectiveness of the Galleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the Galleri MCED tests across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted CSO to determine if a cancer is present. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal detected does not rule out cancer. A test result of Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirmatory diagnostic evaluation by medically establish procedures (e.g., Imaging) to confirmatory diagnostic evaluation of cancer, including due to the cancer being located in a different part of the body. false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only. The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed -- and its performance characteristics were determined -- by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The Galleri test was regulated under CLIA to perform high-complexity testing.新しいナラティブ • Jun 15Overvaluation Risks And NHS Trials Will Spur Future Resilience Market optimism may overestimate Galleri's near-term adoption and pricing power due to regulatory, payer, and competitive pressures. Recent Insider Transactions Derivative • Jun 13President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$43.87, it would amount to US$425k. Since June 2024, Joshua's direct individual holding has increased from 7.93k shares to 120.50k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • May 14First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$3.10 loss per share. Revenue: US$31.8m (up 19% from 1Q 2024). Net loss: US$106.2m (loss narrowed 52% from 1Q 2024). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 22%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.Recent Insider Transactions • May 08CEO & Director recently sold US$3.2m worth of stockOn the 2nd of May, Robert Ragusa sold around 94k shares on-market at roughly US$33.93 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$5.2m.Recent Insider Transactions Derivative • May 01CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 96k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of May. If the sale is conducted around the recent share price of US$36.81, it would amount to US$3.5m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Robert's direct individual holding has increased from 857.00 shares to 127.65k. Company insiders have collectively sold US$4.1m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Apr 30GRAIL, Inc. to Report Q1, 2025 Results on May 13, 2025GRAIL, Inc. announced that they will report Q1, 2025 results After-Market on May 13, 2025お知らせ • Apr 17GRAIL, Inc., Annual General Meeting, May 29, 2025GRAIL, Inc., Annual General Meeting, May 29, 2025.Recent Insider Transactions • Mar 16CEO & Director recently sold US$238k worth of stockOn the 7th of March, Robert Ragusa sold around 8k shares on-market at roughly US$31.21 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$2.0m.Reported Earnings • Feb 21Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$63.54 loss per share. Revenue: US$125.6m (up 35% from FY 2023). Net loss: US$2.03b (loss widened 38% from FY 2023). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$608m net loss in 3 years). Significant insider selling over the past 3 months (US$427k sold).お知らせ • Feb 13GRAIL, Inc. to Report Q4, 2024 Results on Feb 20, 2025GRAIL, Inc. announced that they will report Q4, 2024 results After-Market on Feb 20, 2025Seeking Alpha • Jan 22GRAIL: Cash Burn And Commercialization Timeline Are ProblematicSummary GRAIL is a developer of blood-based cancer tests and is initially targeting the multi-cancer early detection market. This market will be large due to the prevalence of cancer, along with the lack of screening options for some cancers and poor compliance rates with current screening methods. GRAIL's flagship product, Galleri, has enormous potential but faces competition and is years away from generating meaningful revenue. Regulatory approval and reimbursement are critical, with key trials ongoing in support of this. Read the full article on Seeking Alphaお知らせ • Jan 14GRAIL, Inc. Announces Patient-Based Outcomes (PRO) Assessing Patient Prospective from the Pathfinder StudyGRAIL, Inc. announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing. PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. In the PATHFINDER study, general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri® test, and intent towards guideline-recommended screening and repeat MCED testing were assessed. Three instruments used to assess PRO included an adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) for distress, uncertainty and positive experience at MCED test result disclosure, PRO Measurement Information System (PROMIS) Anxiety short-form for anxiety symptoms, the Short Form 12-Item Health Survey (SF-12v2) for health-related quality of Life, and a satisfaction questionnaire. Overall the study demonstrated minimal patient distress associated with MCED testing. Most participants with a NCSD result responded that they were "relieved about my test result." The negative patient-reported impacts associated with a CSD test result were small and returned to baseline within 12 months. High overall satisfaction with the MCED test was reported across participant groups regardless of signal detection status and eventual diagnosis. Most participants reported they were " likely"/"very likely" to adhere to future guideline recommended screening tests as recommended by their healthcare provider.分析記事 • Dec 24Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$572m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$2.2m sold).Seeking Alpha • Dec 16Grail: Lack Of Near Term Catalyst; Market Likely To Lose Interest SoonSummary Grail's net cash balance of $25.71 per share suggests potential undervaluation as it trades at ~$21 per share. However, this cash balance is already part of ongoing expenditure. The risk of failing current NHS trials further complicates the investment outlook. Given these factors, entry at current prices is not favorable. Read the full article on Seeking AlphaRecent Insider Transactions • Nov 21Chief Financial Officer recently sold US$427k worth of stockOn the 18th of November, Aaron Freidin sold around 30k shares on-market at roughly US$14.02 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.7m. Aaron has been a net seller over the last 12 months, reducing personal holdings by US$681k.お知らせ • Nov 19GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer StudyGRAIL, Inc. announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's blood-only approach, tissue analysis and bespoke panel development are not required, enabling simple integration into pharmaceutical clinical trial workflows. In TROPION-Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen (NCT06564844). Assay performance was previously reportedin the Journal of Thoracic Oncologyand presented at the 2023 North America Conference on Lung Cancer. In 2022, GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca's therapies. GRAIL is committed to leveraging its blood-based methylation testing for patient care by developing fit-for-purpose diagnostics to enable precision oncology strategies with biopharma partners.Recent Insider Transactions Derivative • Nov 19Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 32k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of November. If the sale is conducted around the recent share price of US$14.80, it would amount to US$469k. Since June 2024, Aaron's direct individual holding has increased from 1.43k shares to 15.01k. Company insiders have collectively sold US$3.2m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Nov 13Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: US$3.94 loss per share. Net loss: US$125.7m (flat on 3Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.お知らせ • Oct 30GRAIL, Inc. to Report Q3, 2024 Results on Nov 12, 2024GRAIL, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024お知らせ • Oct 25GRAIL, Inc. Presents Initial Results from REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer ConferenceGRAIL, Inc. announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri multi-cancer early detection (MCED) test in routine clinical settings. The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 or older. In this study, a diverse population of veterans from U.S. Department of Veterans Affairs (VA) sites with toxic exposure but with no symptoms suggestive of cancer were included in study enrollment. Initial results showed that among study participants, the veteran cohort had a cancer signal detection rate consistent with other populations that have received the MCED test. The findings were presented during a presentation at the 2024 Early Detection of Cancer Conference (EDCC). Overall, the cancer signal detection rate in this veteran cohort was 1.30% (37/2854 participants; 95% CI: 0.94% - 1.78%), which is consistent with other populations that have received the MCED test (0.88%1 and 0.95%2). Among the 37 participants with a Cancer Signal Detected (CSD) at the time of analysis, 28 completed 180 days of follow-up, and of these, 12 cancer diagnoses were confirmed. More than half of the cases were identified at early stages (I-III) and the most common cancer signal of origin prediction was lung cancer (7). A positive predictive value (PPV), meaning that the test accurately detects a signal for cancer in someone that has cancer, was 42.9%, which is consistent with PPVs from previous Galleri testing datasets. Additional cancers could be diagnosed during the remainder of the one-year follow-up period. The REFLECTION study (NCT05205967) is a multi-center, prospective, non-interventional, cohort study designed to understand the real-world experience of Galleri in clinical settings. This initial analysis included data from seven VA sites with 180 days of post-test follow-up. A total of 2,924 veterans were enrolled in the study at the time of the analysis and 2,854 are analyzable in these initial study data. Within the veteran cohort with data, 70% of participants had been exposed to one or more toxic environmental or occupational hazards during their service, including open burn pits/airborne hazards, Gulf War-related exposures, Agent Orange, radiation and others. The study included recruitment of veterans aged =22 years. The mean age of the cohort was 60 years old and the cohort was 79% male.お知らせ • Oct 24GRAIL, Inc. Announces the Appointment of Sarah Krevans to Its Board of DirectorsGRAIL, Inc. announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health from 2016 to 2022. She was responsible for Sutter Health’s integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Under her leadership, Ms. Krevans advanced clinical programs, innovation, and digital health to make healthcare more accessible for patients. Previously, Ms. Krevans served as chief operating officer, and regional executive officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine’s Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans’ experience as a board member includes serving on many not-for-profit boards and as Chair of the California Association of Hospitals. She currently serves on the board of the Acacium Group and is the incoming Chair of CaringBridge. Ms. Krevans earned master’s degrees in business administration and in public health from the University of California, Berkeley, and a bachelor’s degree from Boston University. Ms. Krevans will serve as a Class II director, for a term expiring at the annual meeting of stockholders to be held in 2026 or until her earlier death, resignation or removal.Recent Insider Transactions • Oct 20CEO & Director recently sold US$1.7m worth of stockOn the 15th of October, Robert Ragusa sold around 123k shares on-market at roughly US$14.02 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Oct 15CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 135k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of October. If the sale is conducted around the recent share price of US$14.49, it would amount to US$2.0m. For the year to December 2022, Robert's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Robert has owned 857.00 shares directly. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Sep 24GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support SuccessSummary GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement. GRAIL's revenue growth hinges on FDA approval and insurance reimbursement for Galleri, potentially transforming cancer detection and driving substantial future sales. Read the full article on Seeking AlphaSeeking Alpha • Sep 09GRAIL's Potential Turnaround: Seeking FDA Approval For GalleriSummary GRAIL's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, GRAIL's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential. Additionally, management’s cost-cutting measures, including a 30% workforce reduction, aim to extend GRAIL's cash runway. Given its promising technology and current valuation below cash value, I rate GRAL a speculative "buy" for investors who understand its unique risks and opportunities. Read the full article on Seeking Alphaお知らせ • Sep 03European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAILIllumina, Inc. announced that it welcomes the European Court of Justice's (ECJ's) judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL. Judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable. Following Illumina's spin-off of GRAIL in June 2024, GRAIL is now an independent public company. Illumina maintains a minority share of 14.5% in GRAIL, and Illumina will continue to support the company with its sequencing technology and suite of services. In the US, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spinoff of GRAIL, thus ending the U.S proceedings.お知らせ • Aug 30GRAIL, Inc. Announces Results of Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision OncologyGRAIL, Inc. announced that detailed findings of the performance of its Galleri multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-free Genome Atlas (CCGA) and PATHFINDER studies. The published data is from an analysis of 420 prostate cancer patients identified in the independent clinical validation portion (substudy 3) of the multi-center, case-control observational study Circulating Cell-freeGenome Atlas (CCGA) study and 18 cases from the prospective intended-use PATHFINDER study. The data were previously presented at the American Association for Cancer Research (AACR) Annual Meeting in March 2024. Results from this analysis showed that of the prostate cancers that were detected by the MCED test, most were clinically significant (93% were intermediate or high grade and 67% were stage III or IV). For detected prostate cancers, the cancer signal of origin (CSO) prediction accuracy was > 90%. Detectability for stage I and II cancers were 4.2% across both studies combined, which is expected with low shedding prostate cancer tumor fraction and is consistent with cfDNA literature in prostate cancer. Test sensitivity of prostate cancer for all stages was 11.2% in substudy CCGA-3. Notably, the MCED test detected no low-grade cancers, 1.9% of intermediate-grade cancers, and only 4.2% of stage I and II cancers across both studies combined. Of the detected cases, 93% were Gleason grade groups 3-5. This analysis demonstrates the MCED test preferentially detects high-grade, clinically significant prostate cancer. This is important because an MCED test, when used in addition to standard-of-care screening, should not exacerbate overdiagnosis of indolent cancers. These findings also suggest that individuals with a cancer signal detected and a prostate CSO prediction should undergo a prompt diagnostic evaluation to determine the presence of aggressive disease for which treatment is generally indicated. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. false-positive prostate cancer is expected to detect cancer signals, and the cancer signal is located.Recent Insider Transactions • Aug 23President recently sold US$1.2m worth of stockOn the 21st of August, Joshua Ofman sold around 74k shares on-market at roughly US$16.25 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Joshua's only on-market trade for the last 12 months.Reported Earnings • Aug 14Second quarter 2024 earnings releasedSecond quarter 2024 results: US$51.06 loss per share. Net loss: US$1.59b (flat on 2Q 2023).お知らせ • Aug 14GRAIL, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2024GRAIL, Inc. reported impairment charges for the second quarter ended June 30, 2024. For the quarter, the company reported goodwill and intangible impairment of $1,420,936,000.お知らせ • Aug 01GRAIL, Inc. to Report Q2, 2024 Results on Aug 13, 2024GRAIL, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 13, 2024業績と収益の成長予測NasdaqGS:GRAL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028284-483-222N/A812/31/2027223-487-255N/A812/31/2026180-433-262N/A83/31/2026156-395-292-291N/A12/31/2025147-408-300-299N/A9/30/2025142-406-330-329N/A6/30/2025134-443-372-370N/A3/31/2025131-1,914-468-465N/A12/31/2024126-2,027-582-577N/A9/30/2024118-2,117-621-613N/A6/30/2024110-2,883-676-665N/A3/31/2024100-1,491-645-633N/A12/31/202393-1,466-609-596N/A1/1/202356-5,399-584-561N/A1/2/202215-1,248-758-688N/A6/30/20211-387-363-295N/A3/31/20210-350-303-263N/A12/31/2020N/A-312-244-232N/A9/30/2020N/A-284-215-212N/A6/30/2020N/A-264-215-213N/A3/31/2020N/A-254-232-229N/A12/31/2019N/A-245N/A-246N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GRAL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: GRAL今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: GRAL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: GRALの収益 ( 23.1% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。高い収益成長: GRALの収益 ( 23.1% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GRAL 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 16:45終値2026/05/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GRAIL, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Catherine Ramsey SchulteBairdKyle MiksonCanaccord GenuitySubhalaxmi NambiGuggenheim Securities, LLC8 その他のアナリストを表示
分析記事 • May 08Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter ResultsA week ago, GRAIL, Inc. ( NASDAQ:GRAL ) came out with a strong set of first-quarter numbers that could potentially lead...
Price Target Changed • Mar 29Price target decreased by 18% to US$72.40Down from US$88.00, the current price target is an average from 5 analysts. New target price is 49% above last closing price of US$48.49. Stock is up 80% over the past year. The company is forecast to post a net loss per share of US$11.02 next year compared to a net loss per share of US$11.11 last year.
Price Target Changed • Feb 22Price target decreased by 13% to US$101Down from US$115, the current price target is an average from 4 analysts. New target price is 100% above last closing price of US$50.21. Stock is up 23% over the past year. The company is forecast to post a net loss per share of US$10.95 next year compared to a net loss per share of US$11.11 last year.
お知らせ • Jan 15GRAIL, Inc. Provides Earnings Guidance for the Full Year 2025GRAIL, Inc. provided earnings guidance for the full year 2025. Revenue is expected to be between $147 million and $148 million, approximately 17% to 18% growth over 2024.
分析記事 • May 08Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter ResultsA week ago, GRAIL, Inc. ( NASDAQ:GRAL ) came out with a strong set of first-quarter numbers that could potentially lead...
ライブニュース • May 07GRAIL Delivers 28% Revenue Growth as Galleri Test Gains Momentum and FDA Advances ReviewQ1 2026 revenue rose 28% year over year, driven by a 37% increase in Galleri test sales to more than 56,000 tests. The company reported an operating loss of $135.8 million and a net loss attributable to common shareholders of $93.2 million in the quarter. The FDA accepted the PMA submission for Galleri, while GRAIL moved to integrate the test into Epic’s electronic health record platform and insiders, including Illumina and key executives, sold shares. For you as an investor, the story here is about commercial traction versus cash burn. Higher Galleri volumes and the 28% revenue growth signal that more physicians and health systems are using the test, which ties directly to management’s focus on broader adoption. At the same time, the operating and net losses underline that GRAIL is still in a capital-intensive phase where scale and regulatory progress are critical. The FDA’s acceptance of the PMA submission for Galleri, based on PATHFINDER 2 and NHS-Galleri trial data, takes the company further along the regulatory path, which can be important for payer discussions and health system uptake. Planned integration into Epic by the end of 2026 could make ordering and tracking Galleri tests easier for clinicians across the US, potentially affecting test volumes over time. Investors may also pay attention to the pattern of insider selling, including by Illumina, as one data point when assessing sentiment around the company’s current trajectory.
ナラティブ更新 • May 07GRAL: Future Returns Will Reflect Trial Outcomes And Reimbursement ProgressNarrative Update on GRAIL Analysts have trimmed their average price target for GRAIL by incorporating lower profit margin assumptions and a slightly higher future P/E of about 101x, following mixed reactions to recent study readouts and reimbursement uncertainty. Analyst Commentary Recent research updates on GRAIL reflect a split tape, with some firms trimming price targets after the NHS Galleri readout and reimbursement uncertainty, while others still see room for upside based on the company’s test portfolio and addressable market.
Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$2.29 loss per share (improved from US$3.10 loss in 1Q 2025). Revenue: US$40.8m (up 28% from 1Q 2025). Net loss: US$93.2m (loss narrowed 12% from 1Q 2025). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
お知らせ • Apr 30GRAIL, Inc., Annual General Meeting, Jun 18, 2026GRAIL, Inc., Annual General Meeting, Jun 18, 2026.
Board Change • Apr 29High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Bill Chase is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 23GRAIL, Inc. to Report Q1, 2026 Results on May 05, 2026GRAIL, Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026
ナラティブ更新 • Apr 19GRAL: Future Returns Will Depend On Upcoming FDA Approval DecisionAnalysts have trimmed GRAIL's average price target to about $67.71 from $72.40. They cited updated models that factor in recent price target cuts following the NHS-Galleri topline readout and lingering uncertainty around broad reimbursement, even as revenue growth and margin assumptions are slightly adjusted.
Recent Insider Transactions • Apr 17CEO & Director recently sold US$6.2m worth of stockOn the 8th of April, Robert Ragusa sold around 124k shares on-market at roughly US$49.92 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$15m.
Recent Insider Transactions Derivative • Apr 08CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 133k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of April. If the sale is conducted around the recent share price of US$51.74, it would amount to US$6.9m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Robert's direct individual holding has increased from 205.85k shares to 218.25k. Company insiders have collectively sold US$23m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Apr 08GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A StrikeoutSummary GRAIL, Inc. (formerly an Illumina subsidiary) remains a buy despite missing the NHS-Galleri trial’s primary endpoint. Galleri’s commercial viability is underscored by 31% YoY U.S. revenue growth and expanding partnerships, including Samsung. A strong cash position ($904.4M) supports operations through 2030, offsetting trial extension and sales force expansion costs. Revised TAM-based valuation implies $78/share (~43% upside), reflecting immense long-term potential for liquid biopsy adoption. Read the full article on Seeking Alpha
お知らせ • Apr 08GRAIL, Inc. Announces Integration of Galleri Test into Epic Electronic Health Record PlatformGRAIL, Inc. announced a collaboration with Epic to bring the Galleri multi-cancer early detection test into one of the nation's most widely used electronic health record platforms, supporting broader adoption across health systems in the United States. Epic is a leading EHR platform used by many of the largest and most advanced health systems. Integration through Epic Aura will allow interested health systems and their healthcare providers to order the Galleri test directly at the point of care, receive results, and manage patient follow-up seamlessly within their existing native EHR and within their existing clinical workflows. Through this integration, clinicians using Epic can access the Galleri test within their native EHR environment, helping to eliminate administrative burden, reduce manual processes, and improve the overall provider and patient experience. Implementation planning began in the first quarter of 2026, including initial integrations and early adopter programs. GRAIL will work closely with Epic and AWS, the preferred cloud provider for GRAIL, along with any interested health systems, community healthcare providers, and retail health clinics to support workflow alignment, training and deployment success. Broad availability is expected by the end of 2026. The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear — when they can be easier to treat and are potentially curable. Galleri is the only available MCED test with demonstrated performance in patients screened for cancer. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market. The Galleri test doubles the number of cancers detected when added to standard of care cancer screening, and has the lowest false positive rate of any MCED test. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
ナラティブ更新 • Apr 05GRAL: Future Returns Will Hinge On Upcoming Regulatory And Coverage MilestonesNarrative Update on GRAIL The analyst price target for GRAIL has been reduced by $11.00. This change reflects recent cuts across firms citing the NHS Galleri study missing its primary endpoint and greater uncertainty around broad reimbursement, even as analysts still reference GRAIL's position in multi cancer early detection and upcoming regulatory and coverage milestones.
Price Target Changed • Mar 29Price target decreased by 18% to US$72.40Down from US$88.00, the current price target is an average from 5 analysts. New target price is 49% above last closing price of US$48.49. Stock is up 80% over the past year. The company is forecast to post a net loss per share of US$11.02 next year compared to a net loss per share of US$11.11 last year.
ナラティブ更新 • Mar 21GRAL: Future Returns Will Depend On NHS Study OutcomeNarrative Update: GRAIL Analyst Price Target Shift The updated analyst fair value estimate for GRAIL has moved from $88.00 to $83.40 as analysts factor in lower published price targets following the NHS Galleri study missing its primary endpoint and increased uncertainty around broad reimbursement, while still modeling higher revenue, stronger profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research shows a mix of optimism and caution around GRAIL, with several firms revising price targets after the NHS Galleri study update and recent quarterly results.
お知らせ • Mar 13+ 1 more updateGRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026GRAIL, Inc. announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. Ragusa will remain on GRAIL's Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. Ofman joined GRAIL in 2019 and brings extensive experience in clinical medicine, biopharmaceutical leadership, health policy and precision medicine. He has served on numerous industry Boards, including BIO and the Precision Medicine Coalition. Before joining GRAIL, Ofman spent more than 15 years at Amgen, most recently as Senior Vice President, Global Value, Access and Policy. Earlier in his career, he was a faculty member in the Department of Medicine and Health Services Research at the UCLA School of Medicine and the Division of Digestive Diseases at Cedars-Sinai Medical Center, and served as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp.
Recent Insider Transactions • Mar 11CEO & Director recently sold US$409k worth of stockOn the 9th of March, Robert Ragusa sold around 8k shares on-market at roughly US$48.48 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$7.4m.
新しいナラティブ • Mar 08Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection PotentialCatalysts About GRAIL GRAIL focuses on multi cancer early detection through its Galleri screening test and related clinical programs. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Mar 06GRAL: Future Returns Will Hinge On NHS Study And FDA DecisionThe analyst fair value estimate for Grail has been trimmed from $114.50 to $88.00 as analysts factor in lower revenue growth and profit margin assumptions following the NHS Galleri readout and increased uncertainty around broad reimbursement. Analyst Commentary Street research on Grail has shifted meaningfully following the NHS Galleri top line readout, with several firms reducing price targets and reassessing the risk and reward profile around Galleri adoption and reimbursement.
Recent Insider Transactions Derivative • Mar 03CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 41k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$53.23, it would amount to US$2.2m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Robert's direct individual holding has increased from 127.65k shares to 173.43k. Company insiders have collectively sold US$20m more than they bought, via options and on-market transactions in the last 12 months.
新しいナラティブ • Feb 22NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening AdoptionCatalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?
Price Target Changed • Feb 22Price target decreased by 13% to US$101Down from US$115, the current price target is an average from 4 analysts. New target price is 100% above last closing price of US$50.21. Stock is up 23% over the past year. The company is forecast to post a net loss per share of US$10.95 next year compared to a net loss per share of US$11.11 last year.
New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 3.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$539m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Significant insider selling over the past 3 months (US$7.6m sold).
Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$11.11 loss per share (improved from US$63.54 loss in FY 2024). Revenue: US$147.2m (up 17% from FY 2024). Net loss: US$408.4m (loss narrowed 80% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
ナラティブ更新 • Feb 20GRAL: Future Returns Will Hinge On Upcoming NHS Trial ReadoutThe average analyst price target for Grail has edged down by $0.50 to about $114.50, as analysts balance optimism around upcoming trial readouts and potential regulatory milestones with a more cautious stance after the stock's very large move earlier in 2025 and ongoing execution risks. Analyst Commentary Recent research on Grail reflects a mix of enthusiasm for its position in multi cancer early detection and caution around valuation and execution timelines.
お知らせ • Feb 20GRAIL, Inc. Announces NHS Galleri Trial Demonstrates A Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection RateGRAIL, Inc. announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years in 142,000 demographically representative participants aged 50 to 77. The clinical performance of Galleri has been rigorously established in several studies, and the NHS-Galleri trial was designed to demonstrate population-level impact through the reduction of late stage cancer diagnoses and increased cancer detection rate within the NHS to inform a decision about a national screening program in England. For the US market, the Galleri premarket approval application pending review by the FDA also includes metrics from the NHS-Galleri trial that are focused on test performance, clinical validation, and the clinical benefit of detection at Stages I through III, including reduction in Stage IV cancer diagnoses. Key trial results include: The primary endpoint of statistically significant Stage III-IV reduction was not observed. However, there was a favorable trend toward fewer Stage III-IV cancers in a pre-specified group of 12 deadly cancers in the intervention arm after the prevalent screening round. Adding Galleri to standard of care screening resulted in a substantial and clinically meaningful reduction in Stage IV diagnoses compared with standard of care alone across the pre-specified group of 12 deadly cancers. Stage IV diagnoses in these cancers decreased with each year of sequential screening, with a greater than 20% reduction in the second and third rounds. Similar reductions were observed across all cancers. Annual screening with the Galleri test plus standard of care screening resulted in a four-fold improvement in the overall cancer detection rate compared to standard of care screening alone in England for breast, colorectal, cervical and high risk lung cancer. Substantial increase in the absolute number of Stage I-II cancers in the 12 pre-specified deadly cancer types that are typically found in late stages were observed in the intervention arm. Screening with the Galleri test resulted in a substantial reduction in the number of cancers detected clinically through emergency presentation, which are associated with significantly higher mortality and healthcare costs. The Galleri test's performance – positive predictive value (PPV), specificity and Cancer Signal of Origin (CSO) accuracy – was consistent with the range previously reported from GRAIL's North American studies. Importantly, no serious safety concerns were reported in participants who received the Galleri test in the NHS-Galleri trial. Additional analyses are underway to better understand these rich data, and detailed results will be submitted for presentation at the ASCO 2026 Annual Meeting. Of note, there was a higher than anticipated incidence of Stage III cancers in the NHS-Galleri trial. In both the US and the NHS data, the time to diagnostic resolution appears to improve over time as physicians gain experience with the Galleri test and diagnostic workup. The number and distribution of cancer stages across screening rounds suggests the potential for a stronger effect with longer follow up as data matures, and GRAIL plans to extend the trial's follow up period by 6-12 months.
お知らせ • Feb 16GRAIL, Inc. to Report Q4, 2025 Results on Feb 19, 2026GRAIL, Inc. announced that they will report Q4, 2025 results After-Market on Feb 19, 2026
ナラティブ更新 • Feb 04GRAL: Future Returns Will Depend On NHS Readout And Execution ConsistencyNarrative Update Analysts have lifted their price target on GRAIL from $105 to $115, citing refreshed models that reflect updated assumptions for growth, margins and future P/E. Recent research highlights steady execution, the long term Galleri opportunity, and the absence of thesis changing developments in recent results.
お知らせ • Jan 30GRAIL, Inc. Submits FDA Premarket Approval Application for the Galleri®? Multi-Cancer Early Detection TestGRAIL, Inc. announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri®? multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018. The PMA submission is focused on the test performance and safety results from 25,490 consented participants in the US-based PATHFINDER 2 study with one year of follow up and from the prevalent screening round (first year) of the NHS-Galleri trial, the largest, and only, randomized, controlled trial of any MCED test in an intended use population. The submission is also supported by a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated PMA version that has been submitted to the FDA for premarket approval. About the NHS-Galleri trial (NCT05611632) The NHS-Galleri trial is the first and only prospective, randomized, controlled trial to assess the clinical utility and performance of a multi-cancer early detection test for population screening when added to standard care. PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of the Galleri in approximately 35,000 individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. The primary objectives of the study are 1) to evaluate the safety and performance of theGalleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the Galleri MCED test across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted CSO to determine if a cancer is present.
ナラティブ更新 • Jan 20GRAL: Future Returns Will Hinge On NHS Trial And Execution RisksAnalysts have nudged their price target on GRAIL up to $110 from $85, citing steady execution, a modest Q4 revenue beat, and the longer term opportunity for the Galleri test, despite the inherent risks that come with new technologies. Analyst Commentary Analysts see GRAIL's recent results as an incremental step rather than a major reset, with views split between confidence in execution and caution around key milestones like the NHS Galleri trial readout.
お知らせ • Jan 15GRAIL, Inc. Provides Earnings Guidance for the Full Year 2025GRAIL, Inc. provided earnings guidance for the full year 2025. Revenue is expected to be between $147 million and $148 million, approximately 17% to 18% growth over 2024.
ナラティブ更新 • Jan 06GRAL: Long Term MCED Opportunity And Execution Risks Will Shape Future ReturnsAnalysts have raised their price target range for GRAIL to about $85 from around $38, citing updated post-Q3 estimates and what they view as a significant long-term commercial opportunity for the Galleri multi-cancer early detection test, while also highlighting the risks associated with this type of novel technology. Analyst Commentary Bullish Takeaways Bullish analysts see the increase in the price target range to about $85 as a reflection of what they view as a sizeable commercial runway for the Galleri multi cancer early detection test over the long term.
ナラティブ更新 • Dec 16GRAL: Future MCED Policy Shifts Will Drive Upside Despite Execution RisksAnalysts have raised their price target on GRAIL to $105 from $96.67, citing updated post earnings estimates and growing confidence in the long term commercial potential of the Galleri multi cancer early detection platform, despite ongoing technology and regulatory risks. Analyst Commentary Recent Street research reflects a meaningful reset in expectations for GRAIL, with multiple price target increases grounded in updated post earnings models and a clearer view of Galleri's commercial runway.
Recent Insider Transactions • Dec 07CEO & Director recently sold US$3.8m worth of stockOn the 3rd of December, Robert Ragusa sold around 40k shares on-market at roughly US$95.24 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$5.1m. Robert has been a net seller over the last 12 months, reducing personal holdings by US$7.8m.
Recent Insider Transactions Derivative • Dec 04Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of December. If the sale is conducted around the recent share price of US$99.15, it would amount to US$2.5m. Since March 2025, Aaron's direct individual holding has increased from 45.05k shares to 78.95k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.
ナラティブ更新 • Dec 01GRAL: Risks From Clinical Data and Execution Will Remain a Key ConcernAnalysts have raised their price target for GRAIL from approximately $90 to $97 per share, citing strengthened confidence in the company’s long-term growth prospects. This outlook is driven by recent developments and opportunities in multi-cancer early detection.
ナラティブ更新 • Nov 17GRAL: Confidence Will Increase With Upcoming Clinical Data and Legislative ProgressAnalysts have raised their price target for GRAIL from $61.50 to $90.00. This change reflects increased confidence in the company’s long-term prospects and growth potential, following recent updates and a positive outlook on its multi-cancer early detection technology.
New Risk • Nov 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$538m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Significant insider selling over the past 3 months (US$5.7m sold).
お知らせ • Nov 14GRAIL, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.GRAIL, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$2.46 loss per share (improved from US$3.94 loss in 3Q 2024). Revenue: US$36.2m (up 26% from 3Q 2024). Net loss: US$89.0m (loss narrowed 29% from 3Q 2024). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
お知らせ • Nov 08GRAIL, Inc. announced that it has received $324.999987 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd., Samsung C&T CorporationOn November 7, 2025, GRAIL, Inc closed the transaction. The transaction included participation from 17 investors.
ナラティブ更新 • Nov 01GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory ShiftsAnalysts have raised GRAIL's fair value estimate from $56.50 to $61.50 per share, citing greater confidence in the company's platforms, ongoing clinical milestones, and evolving market opportunities as key drivers for the upward revision. Analyst Commentary Bullish Takeaways Bullish analysts highlight growing confidence in GRAIL's platforms.
お知らせ • Oct 30GRAIL, Inc. to Report Q3, 2025 Results on Nov 12, 2025GRAIL, Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
お知らせ • Oct 21Grail, Inc. and University of Oxford to Present Long-Term Data from the Symplify Study Evaluating the Galleri®? Multi-Cancer Early Detection Test in Symptomatic Individuals At the Early Detection of Cancer ConferenceGRAIL, Inc. and the University of Oxford announced that positive long-term results from an extended registry follow-up of the SYMPLIFY study will be presented on Oct. 21 at the Early Detection of Cancer Conference (EDCC) in Portland, Oregon. SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primary care and were referred for diagnostic follow-up for suspicion of cancer. In SYMPLIFY, the Galleri®? test was used to assess blood samples from more than 6,000 participants with symptoms of cancer who followed standard diagnostic pathways. However, as a non-interventional study, the results of the tests were unknown to physicians and did not inform the approach to diagnosis. No MCED results were returned to participants or their clinicians during the study. Previous SYMPLIFY results showed potential of MCED testing in people with symptoms suggestive of cancer Most people diagnosed with cancer visit primary care with symptoms before diagnosis1. The fact that, in all but one of the additional patients diagnosed with cancer, a Galleri CSO prediction correctly identified the cancer type, including in many cases where the symptoms were non-specific, further reinforces the value of the Galleri test's CSO capability.
ナラティブ更新 • Oct 18FDA Approval And NHS Studies Will Transform Cancer DetectionAnalysts have raised their price target on GRAIL significantly, from $43 to $75. They cite growing confidence in the company's platforms, anticipated improvements in test performance, and the potential impact of future legislative changes as reasons for this adjustment.
Recent Insider Transactions • Oct 18CEO & Director recently sold US$499k worth of stockOn the 15th of October, Robert Ragusa sold around 7k shares on-market at roughly US$68.88 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$5.1m. Robert has been a net seller over the last 12 months, reducing personal holdings by US$4.0m.
お知らせ • Oct 18GRAIL, Inc. Announces Positive Performance and Safety Results from its Registrational Pathfind 2 StudyGRAIL, Inc. announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. The largest interventional study of an MCED test in the United States to date, the prospective PATHFINDER 2 study includes 35,878 enrolled participants across the United States and Canada in a broad, intended-use population of adults aged 50 and older with no clinical pinpoint of cancer. Results were presented from a pre-specified analysis of the first 25,578 participants with at least 12 months of follow-up as of Dec. 31, 2024. The likelihood of receiving a cancer diagnosis following a positive test result (positive predictive value) was 61.6%, substantially higher than in the previous PATHFINDER study of Galleri. Since PATHFINDER 2 is a prospective clinical trial where the cancer status of participants is unknown at the outset, episode sensitivity - the ability to detect cancer that could be confirmed within 12 months after the blood draw - is a performance measure of the study. Data from this study will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premium approval (PMA) application, along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated version that GRAIL plans to submit to the FDA for premarket approval. The primary objectives of the study are 1) to evaluate the safety and performance of the Galleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the GalleriMCED test across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal detected does not rule out cancer. A test result of Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirmatory diagnostic evaluation by medically establish procedures (e.g., Imaging) to confirm cancer. The Galleri test was developed -- and its performance characteristics were determined -- by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about GRAIL, Inc. (the "Company"), include the benefits and use of the Galleri test, the potential of the Galleri MCED tests, expectations regarding the final results of the PATHFINDER 2 Study, upcoming events and presentations, the timeline and results of a bridging analysis to the FDA, the applicability of the Galleri test, and the applicability of the Galler test, and the timeline for completion of the PMO and the timeline for completion of The PMO and the first phase of the study.
お知らせ • Oct 17GRAIL, Inc. announced that it expects to receive $110.000075 million in funding from Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd and Samsung C&T CorporationGRAIL, Inc. entered into a stock purchase agreement for issuance of 1,570,308 common shares at a price of $70.05 per share for gross proceeds of $110,000,075.4 on October 16, 2025. The transaction included participation from new investors Samsung Electronics Co., Ltd., Samsung Electronics Singapore Pte. Ltd. and Samsung C&T Corporation. The Private Placement is exempt from the registration requirements of the Securities Act, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) and/or Rule 506 of Regulation D under the Securities Act and in reliance on similar exemptions under applicable state laws. The transaction closing is subject to regulatory approvals.
Recent Insider Transactions Derivative • Oct 16President notifies of intention to sell stockJoshua Ofman intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of October. If the sale is conducted around the recent share price of US$69.29, it would amount to US$1.0m. Since March 2025, Joshua's direct individual holding has increased from 76.44k shares to 166.72k. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Oct 10President recently sold US$5.1m worth of stockOn the 6th of October, Joshua Ofman sold around 81k shares on-market at roughly US$62.50 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Joshua has been a net seller over the last 12 months, reducing personal holdings by US$6.9m.
ナラティブ更新 • Oct 04FDA Approval And NHS Studies Will Transform Cancer DetectionAnalysts have raised their price target for GRAIL from $40.50 to $56.50. They cite strengthened confidence in the company's platforms, positive expectations for future study results, and anticipation of supportive legislative developments.
Recent Insider Transactions Derivative • Oct 03President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of October. If the sale is conducted around the recent share price of US$62.06, it would amount to US$601k. Since December 2024, Joshua's direct individual holding has increased from 72.25k shares to 104.99k. Company insiders have collectively sold US$9.0m more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$501m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
Reported Earnings • Aug 13Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: US$3.19 loss per share (improved from US$51.06 loss in 2Q 2024). Revenue: US$35.5m (up 11% from 2Q 2024). Net loss: US$114.0m (loss narrowed 93% from 2Q 2024). Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
お知らせ • Aug 13GRAIL, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2025GRAIL, Inc. reported impairment charges for the second quarter ended June 30, 2025. For the quarter, the company reported goodwill and intangible impairment of $28,000,000 against $1,420,936,000 a year ago.
お知らせ • Jul 30GRAIL, Inc. to Report Q2, 2025 Results on Aug 12, 2025GRAIL, Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025
Recent Insider Transactions Derivative • Jul 16Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of July. If the sale is conducted around the recent share price of US$40.18, it would amount to US$321k. Since September 2024, Aaron's direct individual holding has increased from 15.01k shares to 83.87k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jul 01President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of June. If the sale is conducted around the recent share price of US$48.39, it would amount to US$469k. Since September 2024, Joshua's direct individual holding has increased from 72.25k shares to 110.81k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Jun 30+ 4 more updatesGRAIL, Inc.(NasdaqGS:GRAL) dropped from Russell Midcap Value IndexGRAIL, Inc.(NasdaqGS:GRAL) dropped from Russell Midcap Value Index
お知らせ • Jun 18GRAIL, Inc. Announces Positive Top-Line Results from The Galleri PATHFINDER 2 Registrational StudyGRAIL, Inc. announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study. PATHFINDER 2 was initiated in 2021 to evaluate the safety and performance of the Galleri®? multi-cancer early detection (MCED) test when added to standard of care single cancer screening in 35,878 adults over 50 years of age with no clinical suspicion of cancer. PATHFINDER 2 study results will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premarket approval application (PMA), along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA bridging analyses to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated version that GRAIL plans to submit to the FDA for premarket approval. The PMA for Galleri is currently in process with a modular submission under a Breakthrough Device Designation from the FDA. GRAIL expects to complete the PMA modular submission in the first half of 2026. Detailed results from the PATHFINDER 2 Study (NCT05155605). PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of Galleri in approximately 35,000 individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. The primary objectives of the study are 1) to evaluate the safety and effectiveness of the Galleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the Galleri MCED tests across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted CSO to determine if a cancer is present. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal detected does not rule out cancer. A test result of Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirmatory diagnostic evaluation by medically establish procedures (e.g., Imaging) to confirmatory diagnostic evaluation of cancer, including due to the cancer being located in a different part of the body. false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only. The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed -- and its performance characteristics were determined -- by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The Galleri test was regulated under CLIA to perform high-complexity testing.
新しいナラティブ • Jun 15Overvaluation Risks And NHS Trials Will Spur Future Resilience Market optimism may overestimate Galleri's near-term adoption and pricing power due to regulatory, payer, and competitive pressures.
Recent Insider Transactions Derivative • Jun 13President notifies of intention to sell stockJoshua Ofman intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$43.87, it would amount to US$425k. Since June 2024, Joshua's direct individual holding has increased from 7.93k shares to 120.50k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • May 14First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$3.10 loss per share. Revenue: US$31.8m (up 19% from 1Q 2024). Net loss: US$106.2m (loss narrowed 52% from 1Q 2024). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 22%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.
Recent Insider Transactions • May 08CEO & Director recently sold US$3.2m worth of stockOn the 2nd of May, Robert Ragusa sold around 94k shares on-market at roughly US$33.93 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$5.2m.
Recent Insider Transactions Derivative • May 01CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 96k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of May. If the sale is conducted around the recent share price of US$36.81, it would amount to US$3.5m. For the year to December 2022, Robert's total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Robert's direct individual holding has increased from 857.00 shares to 127.65k. Company insiders have collectively sold US$4.1m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Apr 30GRAIL, Inc. to Report Q1, 2025 Results on May 13, 2025GRAIL, Inc. announced that they will report Q1, 2025 results After-Market on May 13, 2025
お知らせ • Apr 17GRAIL, Inc., Annual General Meeting, May 29, 2025GRAIL, Inc., Annual General Meeting, May 29, 2025.
Recent Insider Transactions • Mar 16CEO & Director recently sold US$238k worth of stockOn the 7th of March, Robert Ragusa sold around 8k shares on-market at roughly US$31.21 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by US$2.0m.
Reported Earnings • Feb 21Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$63.54 loss per share. Revenue: US$125.6m (up 35% from FY 2023). Net loss: US$2.03b (loss widened 38% from FY 2023). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$608m net loss in 3 years). Significant insider selling over the past 3 months (US$427k sold).
お知らせ • Feb 13GRAIL, Inc. to Report Q4, 2024 Results on Feb 20, 2025GRAIL, Inc. announced that they will report Q4, 2024 results After-Market on Feb 20, 2025
Seeking Alpha • Jan 22GRAIL: Cash Burn And Commercialization Timeline Are ProblematicSummary GRAIL is a developer of blood-based cancer tests and is initially targeting the multi-cancer early detection market. This market will be large due to the prevalence of cancer, along with the lack of screening options for some cancers and poor compliance rates with current screening methods. GRAIL's flagship product, Galleri, has enormous potential but faces competition and is years away from generating meaningful revenue. Regulatory approval and reimbursement are critical, with key trials ongoing in support of this. Read the full article on Seeking Alpha
お知らせ • Jan 14GRAIL, Inc. Announces Patient-Based Outcomes (PRO) Assessing Patient Prospective from the Pathfinder StudyGRAIL, Inc. announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing. PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. In the PATHFINDER study, general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri® test, and intent towards guideline-recommended screening and repeat MCED testing were assessed. Three instruments used to assess PRO included an adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) for distress, uncertainty and positive experience at MCED test result disclosure, PRO Measurement Information System (PROMIS) Anxiety short-form for anxiety symptoms, the Short Form 12-Item Health Survey (SF-12v2) for health-related quality of Life, and a satisfaction questionnaire. Overall the study demonstrated minimal patient distress associated with MCED testing. Most participants with a NCSD result responded that they were "relieved about my test result." The negative patient-reported impacts associated with a CSD test result were small and returned to baseline within 12 months. High overall satisfaction with the MCED test was reported across participant groups regardless of signal detection status and eventual diagnosis. Most participants reported they were " likely"/"very likely" to adhere to future guideline recommended screening tests as recommended by their healthcare provider.
分析記事 • Dec 24Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$572m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$2.2m sold).
Seeking Alpha • Dec 16Grail: Lack Of Near Term Catalyst; Market Likely To Lose Interest SoonSummary Grail's net cash balance of $25.71 per share suggests potential undervaluation as it trades at ~$21 per share. However, this cash balance is already part of ongoing expenditure. The risk of failing current NHS trials further complicates the investment outlook. Given these factors, entry at current prices is not favorable. Read the full article on Seeking Alpha
Recent Insider Transactions • Nov 21Chief Financial Officer recently sold US$427k worth of stockOn the 18th of November, Aaron Freidin sold around 30k shares on-market at roughly US$14.02 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$1.7m. Aaron has been a net seller over the last 12 months, reducing personal holdings by US$681k.
お知らせ • Nov 19GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer StudyGRAIL, Inc. announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's blood-only approach, tissue analysis and bespoke panel development are not required, enabling simple integration into pharmaceutical clinical trial workflows. In TROPION-Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen (NCT06564844). Assay performance was previously reportedin the Journal of Thoracic Oncologyand presented at the 2023 North America Conference on Lung Cancer. In 2022, GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca's therapies. GRAIL is committed to leveraging its blood-based methylation testing for patient care by developing fit-for-purpose diagnostics to enable precision oncology strategies with biopharma partners.
Recent Insider Transactions Derivative • Nov 19Chief Financial Officer notifies of intention to sell stockAaron Freidin intends to sell 32k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of November. If the sale is conducted around the recent share price of US$14.80, it would amount to US$469k. Since June 2024, Aaron's direct individual holding has increased from 1.43k shares to 15.01k. Company insiders have collectively sold US$3.2m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Nov 13Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: US$3.94 loss per share. Net loss: US$125.7m (flat on 3Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
お知らせ • Oct 30GRAIL, Inc. to Report Q3, 2024 Results on Nov 12, 2024GRAIL, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024
お知らせ • Oct 25GRAIL, Inc. Presents Initial Results from REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer ConferenceGRAIL, Inc. announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri multi-cancer early detection (MCED) test in routine clinical settings. The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 or older. In this study, a diverse population of veterans from U.S. Department of Veterans Affairs (VA) sites with toxic exposure but with no symptoms suggestive of cancer were included in study enrollment. Initial results showed that among study participants, the veteran cohort had a cancer signal detection rate consistent with other populations that have received the MCED test. The findings were presented during a presentation at the 2024 Early Detection of Cancer Conference (EDCC). Overall, the cancer signal detection rate in this veteran cohort was 1.30% (37/2854 participants; 95% CI: 0.94% - 1.78%), which is consistent with other populations that have received the MCED test (0.88%1 and 0.95%2). Among the 37 participants with a Cancer Signal Detected (CSD) at the time of analysis, 28 completed 180 days of follow-up, and of these, 12 cancer diagnoses were confirmed. More than half of the cases were identified at early stages (I-III) and the most common cancer signal of origin prediction was lung cancer (7). A positive predictive value (PPV), meaning that the test accurately detects a signal for cancer in someone that has cancer, was 42.9%, which is consistent with PPVs from previous Galleri testing datasets. Additional cancers could be diagnosed during the remainder of the one-year follow-up period. The REFLECTION study (NCT05205967) is a multi-center, prospective, non-interventional, cohort study designed to understand the real-world experience of Galleri in clinical settings. This initial analysis included data from seven VA sites with 180 days of post-test follow-up. A total of 2,924 veterans were enrolled in the study at the time of the analysis and 2,854 are analyzable in these initial study data. Within the veteran cohort with data, 70% of participants had been exposed to one or more toxic environmental or occupational hazards during their service, including open burn pits/airborne hazards, Gulf War-related exposures, Agent Orange, radiation and others. The study included recruitment of veterans aged =22 years. The mean age of the cohort was 60 years old and the cohort was 79% male.
お知らせ • Oct 24GRAIL, Inc. Announces the Appointment of Sarah Krevans to Its Board of DirectorsGRAIL, Inc. announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health from 2016 to 2022. She was responsible for Sutter Health’s integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Under her leadership, Ms. Krevans advanced clinical programs, innovation, and digital health to make healthcare more accessible for patients. Previously, Ms. Krevans served as chief operating officer, and regional executive officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine’s Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans’ experience as a board member includes serving on many not-for-profit boards and as Chair of the California Association of Hospitals. She currently serves on the board of the Acacium Group and is the incoming Chair of CaringBridge. Ms. Krevans earned master’s degrees in business administration and in public health from the University of California, Berkeley, and a bachelor’s degree from Boston University. Ms. Krevans will serve as a Class II director, for a term expiring at the annual meeting of stockholders to be held in 2026 or until her earlier death, resignation or removal.
Recent Insider Transactions • Oct 20CEO & Director recently sold US$1.7m worth of stockOn the 15th of October, Robert Ragusa sold around 123k shares on-market at roughly US$14.02 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Oct 15CEO & Director notifies of intention to sell stockRobert Ragusa intends to sell 135k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of October. If the sale is conducted around the recent share price of US$14.49, it would amount to US$2.0m. For the year to December 2022, Robert's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Robert has owned 857.00 shares directly. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Sep 24GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support SuccessSummary GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement. GRAIL's revenue growth hinges on FDA approval and insurance reimbursement for Galleri, potentially transforming cancer detection and driving substantial future sales. Read the full article on Seeking Alpha
Seeking Alpha • Sep 09GRAIL's Potential Turnaround: Seeking FDA Approval For GalleriSummary GRAIL's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, GRAIL's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential. Additionally, management’s cost-cutting measures, including a 30% workforce reduction, aim to extend GRAIL's cash runway. Given its promising technology and current valuation below cash value, I rate GRAL a speculative "buy" for investors who understand its unique risks and opportunities. Read the full article on Seeking Alpha
お知らせ • Sep 03European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAILIllumina, Inc. announced that it welcomes the European Court of Justice's (ECJ's) judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL. Judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable. Following Illumina's spin-off of GRAIL in June 2024, GRAIL is now an independent public company. Illumina maintains a minority share of 14.5% in GRAIL, and Illumina will continue to support the company with its sequencing technology and suite of services. In the US, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spinoff of GRAIL, thus ending the U.S proceedings.
お知らせ • Aug 30GRAIL, Inc. Announces Results of Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision OncologyGRAIL, Inc. announced that detailed findings of the performance of its Galleri multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-free Genome Atlas (CCGA) and PATHFINDER studies. The published data is from an analysis of 420 prostate cancer patients identified in the independent clinical validation portion (substudy 3) of the multi-center, case-control observational study Circulating Cell-freeGenome Atlas (CCGA) study and 18 cases from the prospective intended-use PATHFINDER study. The data were previously presented at the American Association for Cancer Research (AACR) Annual Meeting in March 2024. Results from this analysis showed that of the prostate cancers that were detected by the MCED test, most were clinically significant (93% were intermediate or high grade and 67% were stage III or IV). For detected prostate cancers, the cancer signal of origin (CSO) prediction accuracy was > 90%. Detectability for stage I and II cancers were 4.2% across both studies combined, which is expected with low shedding prostate cancer tumor fraction and is consistent with cfDNA literature in prostate cancer. Test sensitivity of prostate cancer for all stages was 11.2% in substudy CCGA-3. Notably, the MCED test detected no low-grade cancers, 1.9% of intermediate-grade cancers, and only 4.2% of stage I and II cancers across both studies combined. Of the detected cases, 93% were Gleason grade groups 3-5. This analysis demonstrates the MCED test preferentially detects high-grade, clinically significant prostate cancer. This is important because an MCED test, when used in addition to standard-of-care screening, should not exacerbate overdiagnosis of indolent cancers. These findings also suggest that individuals with a cancer signal detected and a prostate CSO prediction should undergo a prompt diagnostic evaluation to determine the presence of aggressive disease for which treatment is generally indicated. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. false-positive prostate cancer is expected to detect cancer signals, and the cancer signal is located.
Recent Insider Transactions • Aug 23President recently sold US$1.2m worth of stockOn the 21st of August, Joshua Ofman sold around 74k shares on-market at roughly US$16.25 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Joshua's only on-market trade for the last 12 months.
Reported Earnings • Aug 14Second quarter 2024 earnings releasedSecond quarter 2024 results: US$51.06 loss per share. Net loss: US$1.59b (flat on 2Q 2023).
お知らせ • Aug 14GRAIL, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2024GRAIL, Inc. reported impairment charges for the second quarter ended June 30, 2024. For the quarter, the company reported goodwill and intangible impairment of $1,420,936,000.
お知らせ • Aug 01GRAIL, Inc. to Report Q2, 2024 Results on Aug 13, 2024GRAIL, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 13, 2024
